Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
@article{Burris2018RibociclibFT, title={Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer}, author={H. Burris}, journal={Expert Review of Anticancer Therapy}, year={2018}, volume={18}, pages={201 - 213} }
ABSTRACT Introduction: The emergence of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors marked a significant advancement in the treatment of advanced breast cancer. Ribociclib is an orally bioavailable, highly selective inhibitor of CDK4/6. In combination with various endocrine therapies, ribociclib has demonstrated clinical activity as a first-line therapy for patients with HR+, HER2− advanced breast cancer, without compromising the favorable toxicity profile associated with endocrine… CONTINUE READING
Topics from this paper
6 Citations
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
- Medicine
- Expert review of anticancer therapy
- 2020
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
- Medicine
- World journal of gastroenterology
- 2019
- 13
An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication
- Chemistry, Medicine
- 3 Biotech
- 2019
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
- Medicine
- F1000Research
- 2019
- 7
- PDF
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
- Chemistry, Medicine
- European journal of medicinal chemistry
- 2019
- 19
“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
- Chemistry, Medicine
- Front. Oncol.
- 2019
- 24
- PDF
References
SHOWING 1-10 OF 114 REFERENCES
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2017
- 12
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
- Medicine
- The New England journal of medicine
- 2016
- 601
- PDF
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
- Medicine
- The New England journal of medicine
- 2012
- 1,546
- PDF
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
- Medicine
- Breast
- 2016
- 67
- Highly Influential
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
- Biology, Medicine
- Cancer research
- 2016
- 260
- Highly Influential
- PDF
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
- Medicine
- The Lancet. Oncology
- 2015
- 1,119
- PDF
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2017
- 452
- Highly Influential
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
- Medicine
- Breast Cancer Research
- 2015
- 144